NCT04335253View on ClinicalTrials.gov

First-In-Human Study of EOS884448 in Participants with Advanced Cancers.

PHASE1CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

February 18, 2020

Primary Completion Date

April 7, 2022

Study Completion Date

April 7, 2022

Conditions
Advanced Cancer
Interventions
DRUG

EOS884448

Multiple Ascending Dose

Trial Locations (4)

1000

Institut Jules Bordet, Brussels

2610

GZA Ziekenhuizen campus Sint-Augustinus, Antwerp

9000

Universitair Ziekenhuis Gent, Ghent

Unknown

Cliniques universitaires St Luc-UCL, Brussels

Sponsors

Lead Sponsor

iTeos Therapeutics
All Listed Sponsors
collaborator

iTeos Belgium SA

INDUSTRY

lead

iTeos Therapeutics

INDUSTRY

NCT04335253 - First-In-Human Study of EOS884448 in Participants with Advanced Cancers. | Biotech Hunter | Biotech Hunter